A Phase 3 interventional study of E/C/F/TAF and E/C/F/TDF in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 56 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-04.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the efficacy of switching to a fixed-dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing on a regimen consisting of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF), or atazanavir (ATV) + ritonavir (RTV) + emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in virologically suppressed HIV-1 infected women.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria
Medically stable -1 infected women who meet the following criteria:
Documented plasma HIV-1 RNA levels \< 50 copies/mL for ≥ 12 weeks preceding the Screening visit. After reaching HIV-1 RNA \< 50 copies/mL, single values of HIV-1 RNA
≥ 50 copies/mL followed by re-suppression to \< 50 copies/mL is allowed
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will switch to B/F/TAF FDC and receive treatment for 48 weeks.
Drug: B/F/TAF
Participants will remain on their baseline regimen of E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF for 48 weeks.
Drug: E/C/F/TAF · Drug: E/C/F/TDF · Drug: ATV · Drug: RTV · Drug: FTC/TDF
Following Week 48, participants in countries where B/F/TAF is not available may have the option to receive B/F/TAF for up to 48 additional weeks.
Drug: B/F/TAF
Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide
150/150/200/10 mg FDC tablet administered orally once daily with food
Also known as: Genvoya®
150/150/200/300 mg FDC administered orally once daily with food
Also known as: Stribild®
ATV 300 mg capsules administered orally once daily with food
Also known as: Reyataz®
RTV 100 mg tablets administered orally once daily with food
Also known as: Norvir®
200/300 mg tablet administered orally once daily with food
Also known as: Truvada®
Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide
50/200/25 mg FDC tablet administered orally once daily without regard to food
Also known as: Biktarvy®
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Change From Baseline in CD4+ Cell Count at Week 48
Time frame: Baseline; Week 48
Participants were enrolled at study sites in the United States, Russian Federation, Thailand, Dominican Republic, and Uganda. The first participant was screened on 19 February 2016. The last study visit occurred on 26 November 2018.
| Milestone | B/F/TAF | Stay on Baseline Regimen (SBR) |
|---|---|---|
| Started | 234 | 236 |
| Completed | 231 | 231 |
| Not completed | 3 | 5 |
| Withdrew: Pregnancy | 3 | 1 |
| Withdrew: Investigator's discretion | 0 | 2 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Milestone | B/F/TAF | Stay on Baseline Regimen (SBR) |
|---|---|---|
| Started | 231 | 228 |
| Completed | 227 | 224 |
| Not completed | 4 | 4 |
| Withdrew: Lost to follow-up | 3 | 1 |
| Withdrew: Pregnancy | 1 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrew consent | 0 | 1 |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | B/F/TAF | Stay on Baseline Regimen |
|---|---|---|
| Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm | 1.7 | 1.7 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | B/F/TAF | Stay on Baseline Regimen |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm | 95.7 | 95.3 |
| cells/µL | B/F/TAF | Stay on Baseline Regimen |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 48 | 29 ± 159.4 | 26 ± 170.3 |
Collected over First dose date to last dose date (maximum duration: 128.4 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| B/F/TAF (Randomized Phase) | 0/234 (0%) | 7/234 (3%) | 61/234 (26.1%) |
| Stay on Baseline Regimen (Randomized Phase) | 0/236 (0%) | 9/236 (3.8%) | 47/236 (19.9%) |
| Extension Phase B/F/TAF From B/F/TAF | 0/231 (0%) | 8/231 (3.5%) | 52/231 (22.5%) |
| Extension Phase B/F/TAF From Stay on Baseline Regimen | 1/228 (0.4%) | 10/228 (4.4%) | 41/228 (18%) |
| Event | B/F/TAF (Randomized Phase) | Stay on Baseline Regimen (Randomized Phase) | Extension Phase B/F/TAF From B/F/TAF | Extension Phase B/F/TAF From Stay on Baseline Regimen |
|---|---|---|---|---|
| ColitisGastrointestinal disorders | 0/234 | 2/236 | 0/231 | 0/228 |
| Acute myocardial infarctionCardiac disorders | 0/234 | 0/236 | 0/231 | 1/228 |
| Non-cardiac chest painGeneral disorders | 0/234 | 0/236 | 0/231 | 1/228 |
| Cholecystitis acuteHepatobiliary disorders | 0/234 | 0/236 | 0/231 | 1/228 |
| Viral infectionInfections and infestations | 0/234 | 0/236 | 0/231 | 1/228 |
| Joint dislocationInjury, poisoning and procedural complications | 0/234 | 0/236 | 0/231 | 1/228 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/234 | 0/236 | 0/231 | 1/228 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/234 | 1/236 | 0/231 | 1/228 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/234 | 0/236 | 0/231 | 1/228 |
| Foetal deathPregnancy, puerperium and perinatal conditions | 0/234 | 0/236 | 0/231 | 1/228 |
| Event | B/F/TAF (Randomized Phase) | Stay on Baseline Regimen (Randomized Phase) | Extension Phase B/F/TAF From B/F/TAF | Extension Phase B/F/TAF From Stay on Baseline Regimen |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 18/234 | 15/236 | 19/231 | 13/228 |
| Upper respiratory tract infectionInfections and infestations | 15/234 | 14/236 | 19/231 | 15/228 |
| Urinary tract infectionInfections and infestations | 16/234 | 4/236 | 8/231 | 5/228 |
| HeadacheNervous system disorders | 12/234 | 13/236 | 13/231 | 8/228 |
| Vulvovaginal candidiasisInfections and infestations | 12/234 | 9/236 | 9/231 | 9/228 |
The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug.
| Age, Continuous(years) | B/F/TAF | Stay on Baseline Regimen | Total |
|---|---|---|---|
| Mean | 40 ± 9.5 | 40 ± 9.1 | 40 ± 9.3 |
| Sex: Female, Male(Participants) | B/F/TAF | Stay on Baseline Regimen | Total |
|---|---|---|---|
| Female | 234 | 236 | 470 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | B/F/TAF | Stay on Baseline Regimen | Total |
|---|---|---|---|
| Hispanic or Latino | 36 | 38 | 74 |
| Not Hispanic or Latino | 198 | 198 | 396 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | B/F/TAF | Stay on Baseline Regimen | Total |
|---|---|---|---|
| Asian | 48 | 54 | 102 |
| Black | 91 | 83 | 174 |
| White | 66 | 67 | 133 |
| Other | 29 | 32 | 61 |
| Region of Enrollment(Participants) | B/F/TAF | Stay on Baseline Regimen | Total |
|---|---|---|---|
| United States | 36 | 36 | 72 |
| Dominican Republic | 28 | 30 | 58 |
| Uganda | 65 | 62 | 127 |
| Thailand | 47 | 54 | 101 |
| Russia | 58 | 54 | 112 |
| HIV-1 RNA Category(Participants) | B/F/TAF | Stay on Baseline Regimen | Total |
|---|---|---|---|
| < 50 copies/mL | 234 | 233 | 467 |
| ≥ 50 copies/mL | 0 | 3 | 3 |
| CD4 Cell Count(cells/µL) | B/F/TAF | Stay on Baseline Regimen | Total |
|---|---|---|---|
| Mean | 712 ± 268.1 | 738 ± 268.4 | 725 ± 268.3 |
| CD4 Cell Count Category(Participants) | B/F/TAF | Stay on Baseline Regimen | Total |
|---|---|---|---|
| ≥ 50 to < 200 cells/µL | 1 | 1 | 2 |
| ≥ 200 to < 350 cells/µL | 10 | 9 | 19 |
| ≥ 350 to < 500 cells/µL | 33 | 25 | 58 |
| ≥ 500 cells/µL | 190 | 201 | 391 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Feb 2016 to primary completion in Oct 2017, 19 months.
Results were first posted in Nov 2018, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide · Bictegravir